Synvista Therapeutics Inc.

News - Synvista Therapeutics Inc.

Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock

2009-02-24 15:15:00

MONTVALE, N.J., Feb. 24 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc.

Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update

2009-01-28 15:00:00

MONTVALE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc.

Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium

2009-01-12 07:30:00

MONTVALE, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has completed enrollment of its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of the Company's compound alagebrium.

Synvista Notified by NYSE Alternext of Continued Listing Standards Non-Compliance

2008-12-24 12:24:00

Company Expects Its Common Stock to Remain Listed While it Engages in Compliance Process MONTVALE, N.J., Dec. 24 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc.

Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults

2008-12-16 07:30:00

Synvista Therapeutics Technology Provided CML Biomarker Data for Studies MONTVALE, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc.

More News (30 articles) »

News - Synvista Therapeutics Inc.

Breaking News

Streaming Video

Images and Photos

Space Exploration

Science and Research

Technology

My Health